Corrigendum to “Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/β-catenin signaling pathway”. (Cancer Letters, 376 (2016) 178-87 (Cancer Letters (2016) 376(1) (178–187), (S0304383516301744), (10.1016/j.canlet.2016.03.024));Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/β-catenin signaling pathway

Cancer Letters

Volumn 376, Issue 1, 2016, Pages 178-187

  Zheng, Kehong ^a   Zhou, Xinying ^a   Yu, Jinlong ^a   Li, Qiang ^a   Wang, Hui ^b   Li, Mingyi ^b   Zhang, Feifei ^a   Luo, Yuhao ^a   Shen, Zetao ^a   Chen, Fei ^a   Shi, Fujun ^a   Cui, Chunhui ^a   Zhao, Dachuan ^a   Lin, Zhiqun ^a   Zheng, Wei ^a   Zou, Zhaowei ^a   Huang, Zonghai ^a   Zhao, Liang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer (CRC); Epithelial mesenchymal transition (EMT); Frequently rearranged in advanced T cell lymphomas protein (FRAT1); MiR 490 3p; Wnt signaling pathway

Indexed keywords

BETA CATENIN; FRAT1 PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 490-3P; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; FRAT1 PROTEIN, HUMAN; MIRN490 MICRORNA, HUMAN; ONCOPROTEIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH; WNT SIGNALING PATHWAY; CELL MOTION; COLORECTAL TUMOR; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; TIME FACTOR; TUMOR INVASION;

APOPTOSIS; BETA CATENIN; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HCT116 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TIME FACTORS; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84962439376     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.07.030     Document Type: Erratum

References (36)

1. Chen L., Su L., Li J., Zheng Y., Yu B., Yu Y., et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis. Markers 2012, 32:195-202.
2. Wang H., An H., Wang B., Liao Q., Li W., Jin X., et al. miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway. Eur. J. Cancer 2013, 49:3924-3935.
3. Xu L., Zhang Y., Wang H., Zhang G., Ding Y., Zhao L. Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway. J. Transl. Med 2014, 12:244.
4. Sun J., Ding W., Zhi J., Chen W. MiR-200 suppresses metastases of colorectal cancer through ZEB1. Tumor Biol 2015, 10.1007/s13277-015-3822-3.
5. Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol 2012, 30:1926-1933.
6. Zhang L.Y., Liu M., Li X., Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J. Biol. Chem 2013, 288:4035-4047.
7. Valeri N., Braconi C., Gasparini P., Murgia C., Lampis A., Paulus-Hock V., et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014, 25:469-483.
8. Bartels C.L., Tsongalis G.J. [MicroRNAs: novel biomarkers for human cancer]. Ann. Biol. Clin. (Paris) 2010, 68:263-272.
9. Berezikov E., Guryev V., van de Belt J., Wienholds E., Plasterk R.H., Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005, 120:21-24.
10. Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N., Basyuk E., et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005, 309:1573-1576.
11. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
12. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
13. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
14. Dong P., Kaneuchi M., Watari H., Hamada J., Sudo S., Ju J., et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol. Cancer 2011, 10:99.
15. Sreekumar R., Sayan B.S., Mirnezami A.H., Sayan A.E. MicroRNA control of invasion and metastasis pathways. Front. Genet 2011, 2:58.
16. Cristobal I., Madoz-Gurpide J., Manso R., Rojo F., Garcia-Foncillas J. MiR-29c downregulation contributes to metastatic progression in colorectal cancer. Ann. Oncol 2015, 26:2199-2200.
17. Hou M., Cheng Z., Shen H., He S., Li Y., Pan Y., et al. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. Oncotarget 2015, 6:35813-35829.
18. Li W., Chang J., Wang S., Liu X., Peng J., Huang D., et al. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget 2015, 6:24448-24462.
19. Kiga K., Mimuro H., Suzuki M., Shinozaki-Ushiku A., Kobayashi T., Sanada T., et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat. Commun 2014, 5:4497.
20. Liu H., Liu Y., Liu W., Zhang W., Xu J. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat. Commun 2015, 6:8494.
21. Shen J., Xiao Z., Wu W.K., Wang M.H., To K.F., Chen Y., et al. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Res 2015, 75:754-765.
22. Zhang Y.F., Liu L., Ding Y.Q. [Isolation and characterization of human colorectal cancer cell subline with unique metastatic potential in the liver]. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:126-130.
23. Gu H., Yang T., Fu S., Chen X., Guo L., Ni Y. MicroRNA-490-3p inhibits proliferation of A549 lung cancer cells by targeting CCND1. Biochem. Biophys. Res. Commun 2014, 444:104-108.
24. Hamfjord J., Stangeland A.M., Hughes T., Skrede M.L., Tveit K.M., Ikdahl T., et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS ONE 2012, 7:e34150.
25. Xu X., Chen R., Li Z., Huang N., Wu X., Li S., et al. MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFbetaR1. BMC Cancer 2015, 15:1023.
26. Chen S., Chen X., Xiu Y.L., Sun K.X., Zong Z.H., Zhao Y. microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. J. Ovar. Res 2014, 7:84.
27. Cai Y., He J., Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. OncoTargets Ther 2015, 8:2657-2664.
28. Li J., Yang S., Su N., Wang Y., Yu J., Qiu H., et al. Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer. Tumor Biol 2015, 10.1007/s13277-015-3998-6.
29. Li X.L., Zhou J., Chen Z.R., Chng W.J. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J. Gastroenterol 2015, 21:84-93.
30. Jin R., Liu W., Menezes S., Yue F., Zheng M., Kovacevic Z., et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of beta-catenin through mechanisms involving FRAT1 and PAK4. J. Cell Sci 2014, 127:3116-3130.
31. He L., Yang Z., Zhou J., Wang W. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors. Clin. Transl. Oncol 2015, 17:438-445.
32. Wang Y., Liu S., Zhu H., Zhang W., Zhang G., Zhou X., et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int. J. Cancer 2008, 123:561-568.
33. Guo G., Zhong C.L., Liu Y., Mao X.G., Zhang Z., Jin J., et al. Overexpression of FRAT1 is associated with malignant phenotype and poor prognosis in human gliomas. Dis. Markers 2015, 2015:289750.
34. Guo G., Liu B., Zhong C., Zhang X., Mao X., Wang P., et al. FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas. Med. Oncol 2011, 28:1-6.
35. Zhang Y., Yu J.H., Lin X.Y., Miao Y., Han Y., Fan C.F., et al. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch 2011, 459:255-263.
36. Wang Y., Hewitt S.M., Liu S., Zhou X., Zhu H., Zhou C., et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br. J. Cancer 2006, 94:686-691.